Dario Surpasses 100 Scientific Studies, Cementing Leadership Among Digital Health’s Most Evidence-Based Platforms

Growing body of peer-reviewed publications and rigorously reviewed conference research reinforces Dario’s position as trusted partner for organizations seeking to reduce cost, improve outcomes and simplify digital health delivery

NEW YORK, Jan. 21, 2026 /PRNewswire/ — DarioHealth Corp. (NASDAQ: DRIO) (the “Company”, “DarioHealth” or “Dario”), a leader in global digital health, today announced that it has surpassed 100 scientific studies, including peer-reviewed journal publications and peer-reviewed conference abstracts, marking a significant milestone in the Company’s commitment to delivering rigorously validated outcomes for employers, health plans and their members.

Reaching this threshold places Dario among the top tier of digital health vendors by volume and depth of  scientifically reviewed evidence, an important differentiator as self-insured employers, consultants and health plans increasingly demand rigorous proof of measurable impact – not merely engagement metrics or modeled results.

Compared with industry peers, Dario’s body of published research reflects one of the most extensive and mature evidence bases in digital health and includes a substantial number of independent, third party investigator-initiated studies.

Beyond scale, Dario’s research is distinguished by several characteristics that matter directly to purchasers of digital health solutions:

• Large study populations, reflecting real employer and health plan member bases
• Longitudinal designs, with some studies spanning up to two years
• Replication across outcomes, with multiple studies validating key metrics
• Independent validations, including analyses conducted entirely by third-party researchers
• Directly observed outcomes, such as actual claims reduction and measured HbA1c improvement – not simply modeled or estimated results
• Multi-condition evaluations, reflecting how cardiometabolic, behavioral health and musculoskeletal needs intersect in real populations

“For employers and health plans, evidence and scientific rigor are no longer optional – they are foundational,” said Omar Manejwala, MD, Chief Medical Officer at Dario.  “Crossing the 100-study milestone demonstrates that Dario’s outcomes are durable, repeatable and supported by a broad and credible body of scientific research.”

As healthcare purchasers shift toward value-based decision-making and vendor consolidation, Dario’s expanding portfolio of peer-reviewed publications and conference-presented research, published on highly regarded platforms such as the Journal of Medical Internet Research and other leading peer-reviewed medical journals, underscores its role as a trusted, outcomes-driven partner capable of delivering measurable impact at scale.

About DarioHealth Corp. (NASDAQ: DRIO)

DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

Dario’s user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses its expectations regarding continued expansion of its scientific evidence base and future research publications, its belief regarding the durability, repeatability, and scalability of clinical and economic outcomes demonstrated in published studies, anticipated demand from employers, consultants, and health plans for evidence-based digital health solutions, its expectation that published research will support broader adoption, future collaborations, and vendor consolidation opportunities, and its belief regarding its ability to deliver measurable clinical and cost outcomes across multiple conditions . Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
[email protected]
+1-201-785-6310

Rob Halpern
SVP Marketing
[email protected]

Logo – http://mma.prnewswire.com/media/544126/DarioHealth_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/dario-surpasses-100-scientific-studies-cementing-leadership-among-digital-healths-most-evidence-based-platforms-302665906.html

SOURCE DarioHealth Corp.